Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXIMQT)

Drug Name

APX-3330 Drug Info

Synonyms

AR-03; E-3330; APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics; APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics; E-3330 analogs (cancer/retinopathy), ApeX Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
Ocular cancer	2D00-2D07	Discontinued in Phase 2	[2]

Cross-matching ID

PubChem CID: 6439397
TTD Drug ID: DMXIMQT

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting AP endonuclease 1 (APEX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
APX3330	DMU6NBO	Diabetic retinopathy	9B71.0	Phase 2	[4]
5-fluoro-1H-indole-2-carboxylic acid	DM9U1HV	Glioma	2A00.0	Investigative	[5]
1,3-bis(1,3-benzothiazol-2-ylthio)acetone	DMP86R3	Glioma	2A00.0	Investigative	[5]
3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	DMWLIK1	Glioma	2A00.0	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AP endonuclease 1 (APEX1)	TTHGL48	APEX1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035303)
3	Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100.
4	Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19.
5	Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.